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Abstract
Background: Sarcopenia, cachexia and frailty have overlapping features and clinical consequences, but often go
unrecognized. The objective was to detect patients described by clinicians as having sarcopenia, cachexia or frailty
within electronic health records (EHR) and compare clinical variables between cases and matched controls.
Methods: We conducted a case-control study using retrospective data from the Indiana Network for Patient Care
multi-health system database from 2016 to 2017. The computable phenotype combined ICD codes for sarcopenia,
cachexia and frailty, with clinical note text terms for sarcopenia, cachexia and frailty detected using natural
language processing. Cases with these codes or text terms were matched to controls without these codes or text
terms matched on birth year, sex and race. Two physicians reviewed EHR for all cases and a subset of controls.
Comorbidity codes, laboratory values, and other coded clinical variables were compared between groups using
Wilcoxon matched-pair sign-rank test for continuous variables and conditional logistic regression for binary
variables.
Results: Cohorts of 9594 cases and 9594 matched controls were generated. Cases were 59% female, 69% white,
and a median (1st, 3rd quartiles) age 74.9 (62.2, 84.8) years. Most cases were detected by text terms without ICD
codes n = 8285 (86.4%). All cases detected by ICD codes (total n = 1309) also had supportive text terms. Overall
1496 (15.6%) had concurrent terms or codes for two or more of the three conditions (sarcopenia, cachexia or
frailty). Of text term occurrence, 97% were used positively for sarcopenia, 90% for cachexia, and 95% for frailty. The
remaining occurrences were negative uses of the terms or applied to someone other than the patient. Cases had
lower body mass index, albumin and prealbumin, and significantly higher odds ratios for diabetes, hypertension,
cardiovascular and peripheral vascular diseases, chronic kidney disease, liver disease, malignancy, osteoporosis and
fractures (all p < 0.05). Cases were more likely to be prescribed appetite stimulants and caloric supplements.
Conclusions: Patients detected with a computable phenotype for sarcopenia, cachexia and frailty differed from
controls in several important clinical variables. Potential uses include detection among clinical cohorts for targeting
recruitment for research and interventions.
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Background
Skeletal muscle weakness and poor physical performance
develop with aging, complicating many chronic clinical
conditions and influencing outcomes and decisions re-
garding the modality and aggressiveness of treatments.
Terms used to describe this overall skeletal muscle de-
cline include sarcopenia, cachexia and frailty. The terms
used in clinical practice are influenced by the medical
subspecialty and the location of medical care [1], though
these terms may be used interchangeably despite unique
mechanisms and operational definitions [2]. Sarcopenia
is a condition of generalized low muscle mass and
strength, resulting in poor physical performance compli-
cating aging and many chronic diseases [3, 4]. Cachexia
involves catabolism and is tied to nutritional status with
resulting extreme weight loss [2]. Most patients with
cachexia will have loss of muscle mass and strength con-
sistent with sarcopenia, while patients with sarcopenia
may not have cachexia, such as those with sarcopenic
obesity [5]. Frailty is the result of aggregate deficits
impairing overall functional reserve [6, 7], leading to
falls, functional dependence, hospitalizations and other
adverse outcomes. Although also tied to musculoskeletal
function, frailty is a heterogenous syndrome involving
multiple factors including balance, neuropathy, cognitive
function, joint dysfunction, cardiovascular function, co-
morbidities, psychosocial and other factors [8]. Thus,
these concepts of frailty, sarcopenia and cachexia are in-
terrelated. Those with cachexia develop sarcopenia; sar-
copenia decreases mobility resulting in frailty; and the
frail state exacerbates muscular declines [5, 9]. In
addition sarcopenia, cachexia and frailty each contribute
to functional dependence, dysmobility, disability, hospi-
talizations, high healthcare costs and death [10–17].
In 2000, disability due to sarcopenia cost the US
healthcare system an estimated 18.5 billion dollars [18].
With increasing life expectancy, the public health costs
of disability are expected to increase. Studies suggest su-
pervised exercise, dietary supplements and pharmaco-
logic interventions may benefit individuals with
sarcopenia [19, 20], frailty [21] and cachexia [22]. How-
ever, it is critically important from individual and public
health perspectives to identify patients with sarcopenia,
frailty and cachexia early for intervention. However these
conditions are often not recognized due to lack of know-
ledge among providers and of equipment for objective
measures (e.g. grip strength), as well as time pressures in
clinical encounters [23].
Large electronic health record (EHR) datasets combin-
ing clinical text notes with coded data provide an oppor-
tunity to identify patients having specific conditions
from clinical encounters. Natural language processing of
text using computers can enhance capture of informa-
tion by accessing unstructured data from the robust
clinical note repository making up the majority of the
data within EHR. A computable phenotype is a clinical
condition, characteristic, or set of features that can be
determined using a computer algorithm to assess its
presence or absence solely from data in EHRs and ancil-
lary data sources. Computable phenotypes may include
structured data (diagnosis codes, recorded measure-
ments, laboratory values, and medications), unstructured
data (text fields or notes), or combinations of such
variables.
We hypothesized that patients diagnosed or described
by providers in the clinical record as having sarcopenia,
cachexia or frailty could be detected using an EHR based
computable phenotype combining coded and text data.
As evidence of detecting a clinically important pheno-
type, we hypothesized patients identified based on our
computable phenotype would differ regarding clinical
features from randomly selected matched controls.
Methods
Study design
This was a retrospective case-control study performed
using the Indiana Network for Patient Care (INPC), a
large statewide clinical data exchange warehouse includ-
ing over 100 separate healthcare entities including major
hospitals, health networks, and insurance providers
(Fig. 1). The INPC contains data on over 18 million pa-
tients in the form of 7 billion clinical data elements, 1.1
billion encounter records, over 290 million mineable text
reports, and data on drug prescription and dispensing.
Approximately two thirds of Indiana’s population con-
tribute data to INPC during clinical encounters. This
study was conducted in accordance with the Declaration
of Helsinki, and prior to the study the protocol was ap-
proved by the Indiana University Institutional Review
Board. Patients were not contacted during this retro-
spective study in a large EHR database, and the Indiana
University Institutional Review Board approved waiver
of consent.
We generated a computable phenotype based on the
combination of ICD codes for sarcopenia, cachexia and
frailty, and text variants of the words sarcopenia, cach-
exia and frailty. Both ICD9 and 10 codes for frailty (797,
R54) and cachexia (799.4, R64) were assessed. Sarcope-
nia only has an ICD10 code (M62.84), introduced in
2016. Notes were searched for text terms using locally
generated natural language processing software, nDepth.
Text searches included detection of variants such as mis-
spellings and grammatical variants. Software also
assessed term negation (such as “not sarcopenic”).
Eligible patients
Included adult patients (18 years of age and older) hav-
ing encounters and clinical notes within the Indiana
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University Health System and Eskenazi Health Systems
during 2016–2017. The computable phenotyping algo-
rithm was applied to these patients’ records including
additional INPC participating institutions during the
study period. Patients having one or more positive oc-
currences during the study period of either the text
terms or codes were considered as cases having the
computable phenotype. Controls were chosen from the
portion of the population assessed that had no occur-
rences of either the ICD codes or text terms for sarcope-
nia, cachexia or frailty, matched 1:1 to cases on year of
birth (to control for age), sex (male, female) and on race
(black, white, other), as recorded in INPC. The index
date was the earliest occurrence within the study period
of the computable phenotype for cases, or the earliest
encounter within the study period for controls.
Manual validation of computable phenotype
Two clinician investigators reviewed the EHR text
around the detected occurrences to confirm whether the
computable phenotype algorithm was detecting that the
author of the clinical note was attributing the condition
to the patient as “present” or “absent”. The two clini-
cians manually validated all cases detected by the com-
putable phenotype and assigned a value of positive
occurrence indicating the condition is present in the pa-
tient, negative occurrence indicating the patient does
not have the condition (e.g. “not frail” or the description
refers to someone else: “she is caring for her sick, frail
mother”) or uncertain. Occurrences were rated as posi-
tive if both reviewers rated as positive, or if one rated as
positive and the other as uncertain. Occurrences were
rated as negative if both reviewers rated as negative or if
one rated as negative and the other as uncertain. Occur-
rences were rated as uncertain if both reviewers rated as
uncertain or if one reviewer rated as positive and the
other as negative. For feasibility, only a smaller subset of
50 randomly selected patients from among the matched
controls were manually reviewed. Because controls were
based on absence of the computable phenotype terms or
codes, manual review of the controls’ entire clinical text
notes during the study period was necessary rather than
just the text notes near the occurrence of terms or codes
as in cases.
Variables
We extracted additional structured data from INPC on
cases and controls, including demographics (used for
matching and cohort description), height, weight, body
mass index (BMI), diagnosis codes for comorbidities, la-
boratory values (albumin, prealbumin, and hemoglobin
A1C using the closest value to the index date) and hos-
pitalizations. Charlson comorbidity index was calculated
to quantify a patient’s overall disease burden [24]. We
also assessed records for dispensing of glucocorticoids,
dronabinol, megestrol, testosterone and caloric formula
supplements (protein shakes, etc.) through Surescripts.
Formalized assessments of muscle strength, muscle
mass, gait, function, etc. were not accessible and thus
could not be detected or analyzed. In EHR data it is not
generally possible to distinguish whether absence of a
datapoint indicates missing versus absent data.
Statistical analysis
Continuous variables were summarized by median (1st
quartile, 3rd quartile), and categorical variables were
summarized by frequency (percentage). For the compari-
sons between the cases and the controls (total cases and
subgroups of cases from the diagnostic categories of sar-
copenia, cachexia or frailty), Wilcoxon matched-pair
sign-rank test was used for continuous variables, and
conditional logistic regression was used for binary
Fig. 1 Electronic health record data sources. The Indiana Network for Patient Care (INPC) incorporates data from over 100 health care entities
across the state of Indiana. Individual patients may receive care through multiple systems during the study period. To be eligible for this study,
patients were required to have clinical data including text notes from the largest contributors to the INPC, IU Health and Eskenazi Health.
However, full data collection included available records from these institutions and the INPC as a whole
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variables. For comparisons between cases with and with-
out ICD codes, Wilcoxon rank sum test was used for
continuous variables, and Pearson’s chi-square test or
Fisher’s exact test was used for categorical variables as
appropriate. Two-sided p-values < 0.05 were considered
statistically significant.
Results
The computable phenotype detected 10,288 presumptive
cases from 2016 to 2017. After manual review, 9594
(93.3%) were considered confirmed positive cases of a
clinician identifying the patient as sarcopenic, cachectic
or frail. The remaining 694 (6.7%) involved text term use
indicating negation or referring to its presence in a sep-
arate person (e.g. relative). Most cases were detected by
text terms without ICD codes n = 8285 (86.4%). All cases
detected by ICD codes (total n = 1309 (13.6%); sarcope-
nia n = 10, cachexia n = 1011, frailty n = 329, more than
one code n = 41) also had supportive text terms. All text
term occurrences were manually reviewed as described
in the methods, for whether the occurrence indicated a
statement regarding presence or absence for the condi-
tion. When present, sarcopenia terms indicated presence
of the condition 97% of the time (310/318), cachexia
terms 90% of the time (3921/4364), and frailty terms
95% of the time (6821/7144). The rest of the occur-
rences described absence of the conditions. A subset of
50 out of 9594 matched controls were manually
reviewed. None had evidence for missed detection of the
terms or codes for sarcopenia, cachexia or frailty, and
none had other terms sufficient to determine the pres-
ence of these phenotypes.
Table 1A is a cross-tabulation indicating the number
of cases with each of the individual terms/codes for sar-
copenia, cachexia and frailty among the cases. Patients
having either the appropriate text term or the ICD code
were considered as having the medical condition (i.e.
sarcopenia, cachexia and frailty). Patients with an indi-
vidual text term (or code) for one of the three conditions
also frequently had text terms (or codes) for the other
conditions. Overall 1496 (15.6%) cases had terms or
codes for two or more of the three conditions (sarcope-
nia, cachexia or frailty) concurrently in their record (n =
133 had all three conditions; sarcopenia plus cachexia
n = 33; sarcopenia plus frailty n = 57; cachexia plus
frailty n = 1273).
The median (1st, 3rd quartiles) age of cases was
74.9 (62.2, 84.8) years, with 59% being female. Most
were white (69%), 10% black and 21% listed other
race. Cases with sarcopenia, cachexia or frailty dif-
fered from controls in several clinical aspects (Table 2).
The BMI was lower in cases [median 22.1 (18.9, 26.2) kg/
m2] than controls [28.1 (24.6, 32.5) kg/m2]. Cases also had
lower serum albumin (p < 0.0001) and prealbumin (p =
0.0215). Cases had a high odds ratio for diabetes with or
without complications compared to controls. Similarly,
cases had high odds ratio for hypertension, cardiovascular
and peripheral vascular diseases, chronic kidney diseases,
liver disease, malignancy, depression, AIDS and neuro-
logic conditions (all p < 0.0001). Regarding skeletal health,
cases had OR > 3 for osteoporosis and fractures (p <
0.0001). Cases also had higher Charlson comorbidity
index scores and were more frequently hospitalized. Cases
had more prescribing of dronabinol, megestrol, and nutri-
tional caloric supplements (protein shakes, etc.) but less
prescriptions for glucocorticoids and testosterone.
Cases having ICD codes for sarcopenia, cachexia or
frailty were younger [median (1st, 3rd quartiles) of 68.8
(58.3, 82.1) years] compared to those cases detected by
text terms alone (without ICD codes) [75.7 (63.2, 85.1)
years] (Supplemental Table 1). Cases with ICD codes
also had lower BMI than cases without ICD codes. Dia-
betes, hypertension, and chronic kidney disease stages
3–5 associated negatively with having ICD codes among
Table 1 Presence of individual ICD and text terms among the cases (Total N = 9594)
A. Cross-tabulation of ICD codes and text terms. The diagonal shaded cells indicate the total number of patients with each individual ICD code
or text term, while the off-diagonal (unshaded cells) indicate presence of combinations of individual text terms or codes according to row and col-
umn of the cell. The numbers in parentheses indicate the percent out of the total N of 9594.
n (% of Total N) Text sarcopenia Text cachexia Text frailty Code sarcopenia Code cachexia Code frailty
Text sarcopenia 310 (3.2) 160 (1.7) 188 (2.0) 8 (0.1) 41 (0.4) 14 (0.2)
Text cachexia 3921 (40.1) 1239 (12.9) 6 (0.1) 886 (9.2) 108 (1.1)
Text frailty 6821 (71.1) 3 (0.0) 451 (4.7) 285 (3.0)
Code sarcopenia 10 (0.1) 2 (0.0) 1 (0.0)
Code cachexia 1011 (10.5) 38 (0.4)
Code frailty 329 (3.4)
B. Additional information on the presence of ICD codes and text terms.
Any text term All three text terms No text term Any ICD code All three ICD codes No ICD Codes
n (%) 9594 (100) 129 (1.3) 0 (0) 1309 (13.6) 0 (0) 8285 (86.4)
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cases. However, malignancies, AIDS, osteoporosis, and
higher Charlson comorbidity index associated positively
with having ICD codes among cases, possibly reflecting
greater recognition and priority of coding in these sce-
narios. Having ICD codes among cases also associated
positively with treatments directed at sarcopenia such as
use of dronabinol or megestrol.
To determine if the clinical difference from controls
was similar in the groups diagnosed with sarcopenia,
cachexia or frailty, we conducted a sub-analysis of each
group separately and their matched controls, excluding
patients with overlapping codes or text terms for more
than one of these three conditions. In general, the differ-
ences in clinical variables between cases and their
Table 2 Clinical variables for cases and controls. Continuous variables are listed as median (1st, 3rd quartiles) with p value by
Wilcoxon signed rank test. Categorical variables are listed as n (%) with odds ratio, its 95% CI and p value by conditional logistic
regression
Cases Controls Odds Ratio (95% CI) P value
n 9594 9594
Age 74.9 (62.2, 84.8) 74.3 (61.6, 84.2)
Female 5663 (59%) 5663 (59%)
Race
African American 981 (10%) 981 (10%)
White 6599 (69%) 6599 (69%)
Other 2014 (21%) 2014 (21%)
BMI, kg/m2 (n = 7952 cases and 4897 controls) 22.1 (18.9, 26.2) 28.1 (24.6, 32.5) < 0.0001
Weight, kg (n = 8638 cases and 6006 controls) 60.7 (50.5, 73.8) 79.5 (65.9, 94.8) < 0.0001
Albumin, mg/dl (n = 8686 cases and 5409 controls) 3.6 (3.1, 4.0) 4.1 (3.8, 4.3) < 0.0001
Prealbumin, mg/dl (n = 1336 cases and 105 controls) 14 (9, 20) 20 (12, 25) 0.0215
Diabetes with complication 1247 (13) 337 (3.5) 4.33 (3.80, 4.94) < 0.0001
Diabetes without complications 2412 (25.1) 1547 (16.1) 1.80 (1.67, 1.94) < 0.0001
HgbA1C, % (n = 3379 cases and 1624 controls) 5.9 (5.5, 6.7) 6.0 (5.6, 6.7) 0.9205
Hypertension 6009 (62.6) 3621 (37.7) 3.26 (3.04, 3.49) < 0.0001
Cardiovascular disease 6769 (70.6) 3862 (40.3) 4.49 (4.17, 4.85) < 0.0001
Peripheral vascular disease 1809 (18.9) 590 (6.1) 3.76 (3.38, 4.17) < 0.0001
Chronic kidney disease stages 3–5 2142 (22.3) 690 (7.2) 3.96 (3.59, 4.38) < 0.0001
Chronic kidney disease stage 4 636 (6.6) 151 (1.6) 4.51 (3.75, 5.43) < 0.0001
Chronic kidney disease stage 5 or end stage kidney disease 462 (4.8) 63 (0.7) 8.39 (6.33, 11.12) < 0.0001
Any malignancy 2923 (30.5) 949 (9.9) 4.08 (3.75, 4.45) < 0.0001
Liver disease 1011 (10.5) 252 (2.6) 4.41 (3.82, 5.11) < 0.0001
Depression 1396 (14.6) 173 (1.8) 9.32 (7.86, 11.05) < 0.0001
AIDS 102 (1.1) 15 (0.2) 7.69 (4.32, 13.71) < 0.0001
Neurologic conditions 6205 (64.7) 2061 (21.5) 7.47 (6.87, 8.11) < 0.0001
Fractures (excludes fingers, toes, craniofacial fractures) 1094 (11.4) 321 (3.3) 3.78 (3.21, 4.32) < 0.0001
Osteoporosis 1501 (15.6) 604 (6.3) 3.03 (2.72, 3.37) < 0.0001
Charlson comorbidity index value 3 (1,6) 0 (0, 2) < 0.0001
Charlson comorbidity index > 2 5700 (59) 1519 (16) 8.99 (8.22, 9.85) < 0.0001
Number of hospitalizations during 2016 ~ 2017 2 (0, 4) 0 (0, 0) < 0.0001
Selected Medications post-index
Glucocorticoids 1200 (12.5) 1488 (15.5) 0.77 (0.71, 0.84) < 0.0001
Dronabinol 69 (0.7) 5 (0.1) 13.8 (5.57, 34.21) < 0.0001
Megestrol 93 (1.0) 19 (0.2) 4.90 (2.99, 8.02) < 0.0001
Caloric Supplement 30 (0.3) 12 (0.1) 2.50 (1.28, 4.88) 0.0073
Testosterone 14 (0.2) 36 (0.4) 0.39 (0.21, 0.72) 0.0027
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matched controls were similar in magnitude and direc-
tion when analyzing patient with sarcopenia, cachexia or
frailty separately (Supplemental Tables 2a, b and c) as
those seen analyzing them together (Table 2). BMI was
lowest in the cachexia group. The patients diagnosed
with frailty were generally older (median 80.2 years) than
those diagnosed with sarcopenia or cachexia (median
64.5 and 63.1 years, respectively) and thus the frailty
group had higher proportions of patients with some
chronic conditions including diabetes, hypertension, car-
diovascular disease, kidney disease, osteoporosis and
fractures. However, the proportion of patients with
Charlson comorbidity index values over 2 were similar
between those with sarcopenia, cachexia or frailty, but in
each category was higher than matched controls.
Discussion
We detected patients having the presence of sarcope-
nia, cachexia or frailty in the EHR using a comput-
able phenotype incorporating both ICD codes and
text terms. Most patients did not have an ICD code
to accompany the use of text descriptors. Of note the
sarcopenia code was rarely used, accounting for only
10 patients while text terms described sarcopenia in
310 patients in the same time period. This may repre-
sent underutilization of the code due to it only being
introduced in 2016 [25]. Of the three terms, cachexia
was the most likely to be accompanied by an ICD
code. However, all terms appeared much more often
as text terms than as ICD codes. Clinicians also fre-
quently appeared to use these terms interchangeably,
with overlap in their use in 15.6%, occasionally within
the same note, suggesting that clinicians may perceive
the clinical similarity, and consistent with the re-
search literature surrounding these constructs [5, 9].
Even when the clinicians identify sarcopenia, cach-
exia or frailty by terms in their notes, these diagnostic
codes were only applied 13.6% of the time. The rea-
sons for non-coding may include the clinician’s per-
ceived lesser importance of these medical conditions
or a tendency to code only for the primary diseases
for which they are seeing the patient. Thus, relying
on ICD codes alone for detection in the EHR is insuf-
ficient. This finding has clinical relevance because
failure to attribute sufficient importance to sarcope-
nia, cachexia and frailty in the EHR might correspond
to failing to target treatment to these conditions. The
cases were more likely to have ICD codes if they were
male, black, or had malignancy, AIDS, or osteopor-
osis, or had higher Charlson comorbidity index sug-
gesting greater recognition and coding in these
conditions or with greater burden of disease. In a
busy clinical practice, sarcopenia, cachexia and frailty
may not be diagnosed or coded during physician
encounters due to focus on other urgent issues and
addressing secondary issues such as skeletal muscle
loss may be deferred, delaying detection and
treatment.
Cases detected had evidence of systemic disease in-
cluding more frequent diabetes, hypertension, cardiovas-
cular, peripheral vascular disease, kidney disease, liver
disease and malignancy than controls. Cases also had
8.99-fold increased odds of having a Charlson comorbid-
ity index of > 2. Given their larger disease burden, it is
not surprising that cases had more hospitalizations dur-
ing the study period. Similarly, individuals with these
conditions of poor muscle health also had higher odds
of fractures. In addition, cases had a poorer nutritional
status as suggested by lower BMI, albumin and pre-
albumin.
Polypharmacy is well documented in frail adults
and thought to have a bidirectional effect with tem-
poral associative studies showing that high medication
burden may be a cause for frailty, as well as a result
[26]. We did not address overall medication burden
in this analysis, but instead focused on use of caloric
supplement and appetite stimulants, though overall
the numbers of patients prescribed these were small.
It is possible that caloric supplements (protein shakes,
etc.) were not fully captured as these do not require
a prescription. The use of megesterol and dronabinol
in cases compared to controls is consistent with clin-
ical efforts to manage this cachexia and weight loss
[27, 28]. In addition, cases having ICD codes were
more likely to receive directed pharmacological treat-
ments. Although testosterone has been used for sar-
copenia treatment [29], fewer cases were receiving
testosterone than controls. This implies that providers
were not prescribing testosterone for this purpose in
these sicker patients.
Strengths of our analysis include the large sample size,
manual validation of cases and the result that our com-
putable phenotype reliably detected patients that clini-
cians were diagnosing with sarcopenia, cachexia or
frailty. The large sample size with a range of age, gender
and race included allows generalizability of results to de-
tect sarcopenia, cachexia or frailty diagnoses within the
EHR across a wide range of ages and conditions. Our
limitations include that our methods cannot detect sar-
copenia, cachexia or frailty if the clinician has not made
the diagnosis or documented the codes or the appropri-
ate text in the notes. Additionally, objective assessments
for sarcopenia, cachexia or frailty were not performed,
therefore the occurrence of codes or terms in EHR does
not guarantee that the conditions are present, but only
implies that the provider detected or interpreted evi-
dence of these conditions. This results in a potential de-
tection bias and it is likely that our computable
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phenotype is detecting primarily the sicker patients with
these conditions or those with more severe sarcopenia,
cachexia or frailty. More mild versions of the clinical
phenotypes would thus be missed. Since we are unable
to capture scenarios where clinicians failed to detect or
mention evidence for sarcopenia, cachexia or frailty, this
results in a potentially a large number of missed cases
and could introduced a misclassification bias into our
analysis if some controls might have clinical features of
sarcopenia, cachexia or frailty without documentation.
Such misclassification would be likely to decrease the
differences between cases and controls for various com-
parisons. Despite this our groups had significant differ-
ences in multiple clinical parameters suggesting that we
are truly detecting different groups of patients.
We also found the differences in clinical variables be-
tween cases and their matched controls were similar in
magnitude and direction when analyzing patients with
sarcopenia, cachexia or frailty separately. Overall, our
findings, including the considerable overlap in applica-
tion of these diagnoses, suggest a lack of standardized
approach among the general clinicians to both reliably
detect these conditions or to differentiate between them.
Given that the computable phenotype is dependent on
what the clinician labels the patient’s condition, without
access to objective measurements we are not able to tell
which of the conditions should be most accurately ap-
plied to the patient (or if more than one is appropriate).
To overcome these biases and limitations, future studies
would require further validation of the computable
phenotype using objective physical measurements in re-
cruited subjects.
Conclusions
We validated a computable phenotype to detect diag-
nosed sarcopenia, cachexia and frailty among patients
within EHR. This computable phenotype used the text
terms and grammatical variants of the words sarcopenia,
cachexia and frailty along with and their associated ICD
codes [sarcopenia (M62.84), cachexia (799.4, R64), frailty
(797, R54)], which reliably indicated that the clinical
provider was labeling the patient as having these condi-
tions. Cases detected in the EHR differed from controls
in the frequency of several important comorbidities and
number of hospitalizations indicating a clinically mean-
ingful computable phenotype is being detected. Further
work is needed to increase electronic capture in the
EHR itself of physical measures and components of
these physical phenotypes to enable greater detection,
differentiation and intervention on a population health
level. Such a computable phenotype has wide ranging
potential uses clinically in detecting patients at risk for
disability, as well as identification for research recruit-
ment for clinical trials.
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